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Abstract: One of the current challenge in Alzheimer’s disease (AD) is the identification of reliable biomarkers that 
might improve diagnostic accuracy, possibly correlating with the disease progression and patient’s response to 
therapy. As the clinically validated AD biomarkers evaluate cerebrospinal fluid (CSF) parameters, the need for less 
invasive diagnostic markers is well evident. To this respect, blood circulating cytokines or growth factors have pro-
vided some encouraging results, even though no clinically validated to date. In 2007 Ray et al suggested a panel of 
18 circulating molecules that might increase AD diagnostic accuracy. In an attempt of replicating their data, we de-
signed a multiplex fluorimetric assay comprising 16 independent analytes and covering 15 out of the 18 described 
proteins. We collected serum samples from three diagnostic groups: probable AD (n=33), matched healthy controls 
(CNT, n=23) and non AD demented (NAD, n=14). After correction for age, we found an increased level of EGF-1 in AD 
in comparison to CNT and NAD, while an increase of TRAIL-R4 was found in NAD. However, evaluation of specificity/
sensitivity by ROC curve analysis gave weak evidence of diagnostic accuracy (area under the curve = 0.63 and 0.66 
for EGF and TRAIL-R4, respectively). Finally, we tried to find a diagnostic classifier by a multivariate algorithm. We 
found indication of diagnostic evidence for AD only, while NAD samples did not show a diagnostic pattern. 
Keywords: Alzheimer’s disease, diagnosis, peripheral biomarkers, multiplex analysis, EGF-1, multivariate classifier, 
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Introduction
Alzheimer’s disease (AD) is a prevalent type of 
dementia whose social and sanitary burden is 
expected to raise in the next future due to gen-
eral population aging [1]. No disease-modifying 
therapy is currently available, and a second 
important limitation is the lack of reliable and 
non invasive biomarkers of the pathology [2]. 
Currently, AD is diagnosed by a multitasking 
process involving exclusion of other possible 
cause of dementia, neuropsychological tests, 
imaging and cerebrospinal fluid (CSF) assess-
ment of the proteins amyloid-beta 42 (Aβ42), 
MAPT (tau) and phospho-MAPT [2-4]. However, 
the latter biomarkers, though clinically validat-
ed, are not routinely used and are not ideal in a 
perspective of mass-screening to find early AD 
alteration in the general population. To this 
respect, blood-derived circulating biomarkers 
would be a better solution, but to date, despite 
extensive research in the field and some prom-
ising data on plasma Aβ42, no clinical valida-
tion has been proposed [5-7]. One of the possi-
ble explanation of the failure of single marker 
approach is that at peripheral level the clinical 
picture is much more variable and concurrent 
pathologies or medications might act as con-
founding factors. Also for this reason, a multi-
plexing approach evaluating at the same time a 
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panel of different circulating molecules has the 
potential to aid in finding an AD diagnostic sig-
nature [8-10]. This was done with promising 
results by Ray et al, who starting from the 
assessment of a panel of 18 plasma circulating 
molecules developed an algorithm discriminat-
ing AD from controls and even mild cognitive 
impairment (MCI) subjects that had converted 
to AD from MCI without conversion [11]. In an 
attempt of replicating this panel and shifting 
the analysis to serum as biologic material, we 
measured with a multiplex technology 16 circu-
lating factors covering 15 of the 18 already 
described molecules in probable AD patients, 
non AD demented and cognitively healthy 
controls.
Materials and methods
Patients recruitment
Patients were consecutively enrolled by the 
Neurology Unit at the clinical center 
“Multimedica” (Castellanza, Varese, Italy). They 
were classified as probable AD (n=33, mean 
age at inclusion ± standard deviation: 76.8 ± 
7.5 years; female percentage: 0.69) according 
to the NINCS-ADRA international criteria [12]. 
Non AD demented (n=13, mean age at inclu-
sion ± standard deviation: 78.9 ± 4.4 years; 
female percentage: 0.69) were diagnosed with 
a different type of dementia [vascular dementia 
(n=4), frontotemporal dementia (n=4), cortico-
basal degeneration (n=1), Lewy bodies disease 
(n=1), progressive supranuclear palsy (n=1), 
unspecified non AD dementia (n=2)]. Healthy 
controls (n=24, mean age at inclusion ± stan-
dard deviation: 74.7± 8.6 years; female per-
centage: 0.55) were not cognitively affected as 
clinically ascertained at recruitment. 
Experiments involving human subjects were in 
accordance to Declaration of Helsinki and 
approved by local ethical committees.
Biologic material preparation and assay de-
scription
Fasting blood was collected by venipuncture, 
divided into 5 aliquots of 1.5 mL and stored at 
room temperature for 15 minutes to allow coag-
ulation. Each aliquot was then centrifuged for 
10 minutes at 4000 rpm and the supernatant 
(serum fraction) was transferred into a new 1.5 
mL tube and immediately frozen. Serum was 
stored at -80°C with constant temperature 
monitoring until required.
One aliquot of serum (25 µL) was used for a 
custom-made slide-based multiplex assay (Ray 
Biotech Inc, Norcross, GA, USA) of a panel of 
molecules including: Angiopoietin-2 (ANG2); 
epidermal growth factor (EGF); granulocyte col-
ony stimulating factor (G-CSF); growth regulat-
ed oncogene-alpha (GRO); intercellular adhe-
sion molecule-1 (ICAM-1); insulin-like growth 
factor binding protein-6 (IGFBP-6); interleukin-1 
alpha (IL-1α); interleukin-8 (IL-8); interleukin-11 
(IL-11); monocyte chemotactic protein-3 (MCP-
3); macrophage colony stimulating factor 
(M-CSF); macrophage inflammatory protein 
1delta (MIP-1δ); pulmonary-activation-regulat-
ed-chemokine (PARC); platelet-derived growth 
factor-BB (PDGF-BB), regulated and normal T 
cell expressed (RANTES); TNF-related apopto-
sis-inducing ligand receptor 4 (TRAIL R4).
Briefly, using a multiplexed sandwich ELISA-
based technology, samples (arrayed in quadru-
plicate), after a room temperature blocking 
step were incubated overnight to get the target 
cytokine trapped on the glass surface. The 
array was washed on an orbital shaker, incu-
bated with a primary antibodies cocktail for 2 
hours and subsequently with a fluorogenic sec-
ondary mix for one hour. Finally, it was gently 
centrifuged in a 50 mL conical tube to com-
pletely dry the surface. Then, the slide was 
placed in a high resolution scanner (Agilent 
Technologies, USA) for fluorescence quantifica-
tion. Raw fluorescence spots were quantified 
using a macro implemented in ImageJ (www.
nih.gov/ImageJ). Fluorescence values were 
also converted into a graphical representation 
by association of the corrected fluorescence 
level to an arbitrary colorimetric scale. 
Fluorescence values corrected for background 
were converted to molar concentrations thanks 
to standard curve (linear or logaritmic depend-
ing on the best fit for each molecule). Only stan-
dard curves with r2>0.9 were considered.
Classifier development
A multilayer feed-forward artificial neural net-
work (ANN) and a naïve bayes (NB) classifier 
were employed for the classification of the 
cases [13, 14]. For training and validation pur-
poses, the available data was divided into two 
subsets; the 80% of the data was used for 
Serum molecules for the differential diagnosis of AD
42 Am J Neurodegener Dis 2013;2(1):40-45
training (training set, including 27 AD, 11 NAD 
and 18 CNT) and the 20% of the data was used 
for validation (testing set, including 6 AD, 3 NAD 
and 5 CNT).
As far as the ANN is concerned, the Back 
Propagation (BP) algorithm was used for the 
learning process, while the mean squared nor-
malized error (mse) was used as the network 
performance function. The input layer of the 
ANN consists of 16 nodes, one for each of the 
variables. The output layer contains 3 neurons, 
one for each class of the dataset. In order to 
identify the optimal topology of the network, we 
trained and tested 289 ANNs with two hidden 
layers and hidden neurons from 5 to 22 for 
each layer. All neurons in the hidden and the 
output layers of the networks use a sigmoidal 
activation function. During this procedure, the 
learning rate and the momentum of the BP 
algorithm were set equal to 0.01 and 0.9, 
respectively.
Statistics
Univariate analysis was conducted by ANOVA 
and multivariate with ANCOVA considering age 
as covariate. In case of non normal distribution, 
associations were tested with non parametric 
Kruskall-Wallis test. ROC curve analysis was 
performed by a free online resource (http://
vassarstats.net/).
Results
Multiplex assessment of serum molecules 
level
The quantification of the panel of 16 serum cir-
culating molecules in the three different groups 
is summarized in Table 1. After performing 
ANCOVA analysis correcting for age, almost all 
the assessed analytes did not change among 
groups, with the exception of EGF and TRAIL-R4. 
EGF serum level resulted higher in AD than CNT 
and NAD, the latter having the lowest level of 
the growth factor. As for TRAIL-R4, its level was 
considerably higher in NAD in comparison to 
the other groups, where the assessed mean 
level was comparable.
A color-based representation of the single vari-
able measured in each subject is shown in 
Figure 1A. Fluorescence signal intensity, cor-
rected for background, was transformed into a 
colored square, according to a reference scale. 
Table 1. Single variable assay for the panel of circulating molecules assessed in serum of patients
PROTEIN (alias)
CONTROL
(n=23)
mean ± SE (pg/mL)
NAD
(n=14)
mean ± SE (pg/mL)
AD
(n=33)
mean ± SE (pg/mL)
ANG-2 1433.8 ± 284.5 2243.9 ± 622.3 1612.5 ± 112.5
EGF 52.7 ± 13.3 28.5 ± 7.9 75.9 ± 13.2*
G-CSF 98.9 ± 45.6 161.4 ± 44.8 92.4 ± 16.1
GRO 3340.9 ± 543.8 2984.5 ± 827.7 3314.2 ± 576.9
ICAM-1 78215.7 ± 14139.9 125879.5 ± 34912.7 135021.8 ± 23504.3
IGFBP-6 27234.0 ± 2751.1 27026.0 ± 7495.9 25773.2 ± 4486.5
IL-1A 7.2 ± 4.3 7.9 ± 2.2 22.4 ± 3.9
CXCL8 (IL-8) 81.7 ± 13.8 88.3 ± 24.5 96.7 ± 16.8
IL-11 1000.3 ± 265.3 1175.2 ± 325.9 683.4 ± 118.9
CCL7 (MCP-3) 1505.1 ± 541.4 3748.5 ± 1039.6 1650.9 ± 287.4
M-CSF 143.7 ± 55.6 245.3 ± 68.0 114.1 ± 19.9
CCL15 (MIP-1delta) 2366.0 ± 157.3 2283.3 ± 633.3 2076.5 ± 361.5
CCL18 (PAR-C) 23324.3 ± 2715.1 23885.9 ± 6624.8 17197.1 ± 2993.6
PDGF-BB 4108.4 ± 143.3 4126.6 ± 1144.5 4048.3 ± 704.7
CCL5 (RANTES) 27178.5 ± 1857.3 24695.9 ± 6849.4 24582.3 ± 4279.2
TRAIL R4 136.9 ± 57.1 1248.4 ± 37.9** 217.7 ± 37.9
*ANCOVA p-value: 0.013; Kruskal-Wallis p-value: 0.0067. **ANCOVA p-value: 0.02; Kruskal-Wallis p-value: 0.045. CCL, chemo-
kine that contains a C-C motif; CXCL, chemokine that contains a C-X-C motif; SE: standard error; AD: Alzheimer’s disease; NAD: 
non AD dementia.
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This representation highlights the increased 
level of EGF in AD subjects, while TRAIL-R4 
mean increase in NAD was mainly due to the 
contribution of a limited number of cases. 
We have then plotted the specificity/sensitivity 
graph and run a ROC analysis for EGF and 
TRAIL-R4 [Figure 1B and 1C]. EGF ROC analysis 
was conducted for discriminating AD from NAD/
CNT, while for TRAIL-R4 the hypothesis was to 
differentiate NAD from the other groups. The 
resulting curves were similar for the calculated 
area under the curve (AUC), that was <0.70 in 
both cases. 
Multivariate analysis and classifier elaboration
Based on the experimental results, the optimal 
artificial neural network (ANN) was found to be 
a network with 15 neurons on the first hidden 
layer and 13 neurons on the second. 
The performance of the classifiers was com-
puted on the testing set (holdout validation). 
The confusion matrices obtained through hold-
out validations are given in Table 2. 
Performance rates of the classifier ANN in pre-
dicting AD dementia regarding the patients of 
the testing set were as follows: sensitivity 
83.3%, specificity 62.5% and accuracy 71.4%. 
The same values for NB were: 83.3% sensitivi-
ty, 87.5% specificity and 85.7% accuracy.
Discussion
Differential diagnosis of AD is still complex and 
in some cases not confirmed at autopsy [15]. 
Figure 1. Multiparametric assessment of serum proteins for the differential diagnosis of Alzheimer’s disease (AD). 
A. The circulating proteins listed in Table 1 were simultaneously measured using a glass slide-based protein ar-
ray as described in Methods. The resulting fluorescence signals were converted to a color code reflecting signal 
intensity after background subtraction. Vertical columns are single patients, horizontal rows are panel proteins as 
identified by the labels on the left. B, C. Receiver operating characteristic (ROC) analysis for EGF and TRAIL-R4. The 
plotted curves were calculated hypothesizing a diagnostic value for Alzheimer’s disease (AD) in the case of EGF and 
for non-AD dementia (NAD) for TRAIL-R4. The reported area-under-the-curve (AUC) value is suggestive of modest 
diagnostic usefulness (for the null hypothesis: AUC =0.50). AD: Alzheimer’s disease; NAD: non AD dementia; CNTR: 
cognitively healthy control.
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Beside the need of a reliable diagnosis for ther-
apeutic purpose, the availability of minimally 
invasive AD biomarkers is an urgent unmet 
issue. In this pilot study we have included three 
different groups of patients having a clinical 
classification and we have performed a multi-
plex assay aimed at finding a possible diagnos-
tic profile. Our approach was not original as for 
the selection of assayed molecules, that were 
almost entirely listed by Ray et al [11]. For tech-
nical reasons linked to cross-reactivity, we were 
able to include in a single array only 15 out of 
18 of the molecules measured in the just cited 
paper. We also assessed the protein GRO that 
was not listed by Ray et al [11] but that was 
recently considered as possible interesting bio-
marker for AD diagnosis [16]. However, this 
should not have been a major limitation in rep-
licating diagnostic accuracy, as according to 
the published data the classification error using 
>10 predictors up to 120 was not remarkably 
increased. In fact, others reported a diagnostic 
classification starting from the same 18 pro-
tein panel but using 16 predictors and a bioin-
formatic elaboration reduced the number of 
predictors down to 5 without affecting diagnos-
tic accuracy [17, 18]. At difference from Ray et 
al, we used serum as biological material instead 
of plasma. Our purpose was to test the diag-
nostic panel in a clinically easy handling type of 
sample, without the need of anticoagulant 
agents, and to add knowledge about this 
option, as to date only plasma was used for rep-
lication of Ray et al. In agreement with other 
studies that attempted a replication [17, 19], 
our results at single predictor level were mostly 
negative, with no difference among groups for 
13 out of 15 molecules. The additional protein 
tested, GRO, did not differ among groups. 
However, it is worth to notice that difficulties in 
replicating the original data might also depend 
on the complex algorithm used by Ray et al 
[11]. Others have tried to differently re-analyze 
their data from the bioinformatic point of view 
and found evidence for the differential diagno-
sis of AD [20]. Our positive finding on EGF 
deserves attention, as our AD group was suffi-
ciently sized (n=33) and an increase of this 
growing factor in AD was independently report-
ed also by [17] and [19], so it is possible that 
further research is warranted on this point, 
even though EGF alone was not a good diag-
nostic predictors in our hands (AUC= 0.63). The 
multiparametric analysis gave some prelimi-
nary suggestions of a possible improvement of 
diagnostic accuracy using the 15 protein panel 
as a whole, as the development of a naïve 
bayes (NB) classifier allowed specificity, sensi-
tivity and accuracy estimation above 83% for 
the discrimination of AD from healthy controls. 
However, this analysis suffers from reduced 
sample size, particularly in the validation step 
and independent replication in larger datasets 
is mandatory. In conclusion, our proposed diag-
nostic panel gave mostly negative findings in 
agreement with the available literature, but 
confirmed in serum the evidence for EGF 
increase in AD patients.
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